EGFR and non-small cell lung carcinoma: In 2010, the first EGFR tyrosine kinase inhibitor (TKI), Gefitinib, had an excellent response rate and progression-free survival (PFS) compared to chemotherapy for patients with mutant EGFR advanced-stage NSCLC [5].